Arbor Biotechnologies

Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

PARMA, Italy & CAMBRIDGE, MA, June 25, 2026 — Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced a milestone for ABO-101,…

Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer

CAMBRIDGE, MA – May 18, 2026 – Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mathew Pletcher, Ph.D., as Chief Scientific Officer, succeeding John Murphy, Ph.D., who is retiring after five…

Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases

CAMBRIDGE, MA – May 12, 2026 – Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announces the presentation of data demonstrating the first precise in vivo genome editing in the brain using Read More The post Arbor…

Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

CAMBRIDGE, MA – April 27, 2026 – Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced three upcoming presentations at the 2026 American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place…

Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines

INCHEON, Korea – October 30, 2025 – Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Biotechnologies, Inc., a leading Read More The…

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs

PARMA, ITALY & CAMBRIDGE, MA, USA – October 6, 2025 – Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a next-generation biotechnology company discovering and developing innovative approaches in genetic medicines, today announced…